Clinical Trial Update: Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 trial of Datopotamab Deruxtecan (Dato-DXd) for non-small cell lung cancer with active brain metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (datopotamab deruxtecan)

Snippet

Sponsor: MedSIR | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN